Darryl Ballard

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

Enzastaurin

Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent

Natural products: An evolving role in future drug discovery

Cellular pathophysiology of ischemic acute kidney injury

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways

Systemic Therapy for Ovarian Cancer: Current Status and New Treatments

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Natural products to drugs: natural product-derived compounds in clinical trials

Malignant Gliomas in Adults

Primary brain tumours in adults

Enzastaurin

Discovery and resupply of pharmacologically active plant-derived natural products: A review

The role of the microcirculation in acute kidney injury

A Perivascular Niche for Brain Tumor Stem Cells

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

Management of glioblastoma: State of the art and future directions

Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy

Marine natural products

Diagnosis and Treatment of Recurrent High-Grade Astrocytoma

In Vivo/Ex Vivo and In Situ Assays Used in Cancer Research: A Brief Review

Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents

Kinase Inhibitors of Marine Origin

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).